CLAIMS:

1. The use of an affinity reagent which binds to LY75 in the manufacture of a medicament for the treatment or prophylaxis of a cancer selected from the group consisting of lymphoma, myeloma, leukaemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer wherein LY75 is expressed in said cancer and wherein said affinity reagent is conjugated to a therapeutic moiety.

2. The use according to claim 1, wherein the lymphoma is selected from the group consisting of non-Hodgkin's lymphoma, Diffuse Large B-Cell Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT), T-Cell/Histiocyte-Rich B-Cell Lymphoma, Burkitt Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma and AngioImmunoblastic T-Cell Lymphoma.

3. The use according to claim 1 or claim 2, wherein the affinity reagent binds specifically to LY75.

4. The use according to any one of claims 1 to 3, wherein the affinity reagent is an antibody, a monoclonal antibody, a chimeric antibody, a human antibody, a humanized antibody, a single chain antibody, a defucosylated antibody or a bispecific antibody, or a functional fragment thereof or antigen-binding portion thereof, or an antibody mimetic.

5. The use according to claim 4, wherein

a) the functional antibody fragment is a UniBody, a domain antibody or a Nanobody; or

b) the antibody mimetic is an Affibody, a DARPin, an Anticalin, an Avimer, a Versabody or a Duocalin.

6. The use according to any one of claims 1 to 5, wherein the therapeutic moiety is a cytotoxic moiety or a radioactive isotope.

7. The use according to claim 6 wherein the cytotoxic moiety is selected from the group consisting of duocarmycins, calicheamicins, maytansines and auristatins, or derivatives thereof.

8. The use according to claim 6 or 7, wherein the affinity reagent is an antibody drug conjugate.

9. A method of detecting, diagnosing and/or screening for or monitoring the progression of a cancer selected from the group consisting of lymphoma, myeloma, leukaemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer wherein LY75 is expressed in said cancer, or of monitoring the effect of a cancer drug or therapy directed to said cancer, in in a biological sample obtained from a subject which comprises:-

a) detecting the presence or level of LY75, or one or more fragments thereof, or the presence or level of nucleic acid encoding LY75, or which comprises detecting a change in the level of either thereof in said subject; or

b) detecting the presence or level of antibodies capable of immunospecific binding to LY75, or one or more fragments thereof.

10. The method according to claim 9 which comprises detecting the presence of LY75, or one or more fragments thereof, or the presence of nucleic acid encoding LY75, in which either (a) the presence of an elevated level of LY75, or said one or more fragments thereof, or an elevated level of nucleic acid encoding LY75 in the subject as compared with the level in a healthy subject, or (b) the presence of a detectable level of LY75, or said one or more fragments thereof, or a detectable level of nucleic acid encoding LY75 in the subject as compared with a corresponding undetectable level in a healthy subject is indicative of the presence of said cancer in said subject.

11. The method according to any one of claims 9 to 10 wherein the presence of LY75, or one or more fragments thereof, is detected using an affinity reagent which binds to LY75.

12. The method according to claim 11 wherein the affinity reagent is as defined in any one of claims 3 to 8.

13. The method according to claim 11 or 12 wherein the affinity reagent contains or is conjugated to a detectable label.

14. The use according to any one of claims 1 to 8 or the method according to any one of claims 9 to 13 wherein the subject is a human.

15. A method for identifying an agent for the treatment or prophylaxis of a cancer selected from the group consisting of lymphoma, myeloma, leukaemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer wherein LY75 is expressed in said cancer, wherein the method comprises (a) contacting LY75, or one or more fragments thereof, with a candidate agent; and (b) determining whether the agent binds to LY75, or said one or more fragments thereof.

16. The method according to claim 15 further comprising the step of testing the ability of an agent which binds to LY75, or one or more fragments thereof, to:-

a) inhibit said cancer; and/or

b) to modulate a physiological function of LY75, inhibit ligand binding to LY75 and/or inhibit a signal transduction pathway mediated by LY75.

17. The use according to claim 1 or the method according to claim 16, wherein the cancer is multiple myeloma or Triple-Negative breast cancer.

CLAIMS:

1. The use of an antibody which binds to LY75 in the manufacture of a medicament for the treatment or prophylaxis of a cancer selected from the group consisting of lymphoma, myeloma, leukaemia, bladder cancer, breast cancer, gastric cancer, esophagus cancer and head and neck cancer wherein LY75 is expressed in said cancer and wherein said antibody is conjugated to a cytotoxic moiety or a radioactive isotope.

2. The use according to claim 1, wherein the lymphoma is selected from the group consisting of non-Hodgkin's lymphoma, Diffuse Large B-Cell Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT), T-Cell/Histiocyte-Rich B-Cell Lymphoma, Burkitt Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma and AngioImmunoblastic T-Cell Lymphoma.

3. The use according to claim 1 or claim 2, wherein the antibody binds specifically to LY75.

4. The use according to any one of claims 1 to 3, wherein the antibody is a monoclonal antibody, a chimeric antibody, a human antibody, a humanized antibody, a single chain antibody, a defucosylated antibody or a bispecific antibody, or antigen-binding portion thereof.

5. The use according to claim 4, wherein the antibody is a domain antibody.

6. The use according to claim 1 wherein the cytotoxic moiety is selected from the group consisting of duocarmycins, calicheamicins, maytansines and auristatins, or derivatives thereof.

7. The use according to any preceding claim, wherein the antibody is an antibody drug conjugate.

8. The use according to claim 1, wherein the cancer is multiple myeloma or Triple-Negative breast cancer.